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Abstract
Background: Artemisia pollen allergy is a major cause of asthma in Northern China.
Possible associations between IgE responses to Artemisia allergen components and
clinical phenotypes have not yet been evaluated. This study was to establish sensiti-
zation patterns of four Artemisia allergens and possible associations with demo-
graphic characteristics and clinical phenotypes in three areas of China.
Methods: Two hundred and forty patients allergic to Artemisia pollen were examined,
178 from Shanxi and 30 from Shandong Provinces in Northern China, and 32 from Yun-
nan Province in Southwestern China. Allergic asthma, rhinitis, conjunctivitis, and eczema
symptoms were diagnosed. All patients’ sera were tested by ImmunoCAP with mugwort
pollen extract and the natural components nArt v 1, nArt ar 2, nArt v 3, and nArt an 7.
Abbreviations: CI, 95% confidence interval; CRD, component-resolved diagnostics; OR, odds ratio; SD, Shandong province, Northern China; SX, Shanxi province, Northern China; YN,
Yunnan province, Southwestern China.
Gao, Fu and Sun contributed equally to this research.
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Results: The frequency of sensitization and the IgE levels of the four components in
Artemisia allergic patients from Southwestern China were significantly lower than in
those from the North. Art v 1 and Art an 7 were the most frequently recognized
allergens (84% and 87%, respectively), followed by Art v 3 (66%) and Art ar 2 (48%).
Patients from Northern China were more likely to have allergic asthma (50%) than
patients from Southwestern China (3%), and being sensitized to more than two aller-
gens increased the risk of allergic asthma, in which co‐sensitization to three major
allergens Art v 1, Art v 3, and Art an 7 is prominent.
Conclusions: Component‐resolved diagnosis of Chinese Artemisia pollen‐allergic
patients helps assess the potential risk of mugwort‐associated allergic asthma.
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1 | INTRODUCTION
Over the past 30 years, there has been a significant increase in the
prevalence of allergy in the Chinese population, and allergy has been
found to be the major factor causing asthma.1,2 A cross‐sectional
study has shown that overall, while about 11.3% of patients in China
with respiratory allergies are sensitized to Artemisia pollen, this value
is much higher in Northern China (>50%). Among the major pollen
species causing seasonal allergic asthma in China, Artemisia pollen
has the highest association index.3-7 The hop (Humulus scandens),
ragweed (Ambrosia artemisiifolia), and goosefoot (Chenopodium album)
pollen seasons overlap with that of Artemisia, but their IgE positive
rate was significantly lower in a survey of a large number of Immu-
noCAP tests in Beijing.5 In some areas in Europe, mugwort (A. vul-
garis) pollen has also been associated with late summer and autumn
hay fever and asthma, but its clinical importance is limited compared
to birch and grass pollen.8
Component‐resolved diagnosis (CRD) enables IgE sensitization
profiles and potential risk to be established, and whether specific IgE
is the result of primary sensitization or cross‐reactivity can also be
determined.9-13 Such information can assist in making the right
choice of immunotherapy, particularly when pollen seasons of differ-
ent allergenic sources overlap.14-19 Seven Artemisia pollen allergens
have been identified and listed in the IUIS database (www.allergen.
org), including the recently added 62 kDa putative galactose oxidase
protein (Art an 7), first purified from sweet wormwood (A. an-
nua).20,21 In earlier studies with nine patients in Europe, using array‐
based profiling of five mugwort allergens, Art v 1, Art v 3, Art v 4,
and Art v 6 were recognized by 60%‐80% patients, with a co‐sensiti-
zation frequency of 60% of three of these four allergens.22 Until
now, only two mugwort major component allergens (Art v 1 and Art
v 3) have been commercially available for component‐resolved diag-
nosis, with the prevalence of Art v 1 around 80% and Art v 3 around
60% in mugwort‐allergic patients from Beijing and Shanxi pro-
vinces.21,23 Previous CRD analyses have revealed Art v 1 as a specific
marker of mugwort pollen sensitization, and it is on the list of the
100 important allergen molecules,19 although significant differences
were found in different geographic areas.24
Currently, conventional diagnosis of Artemisia pollen allergy in
China largely relies on skin prick tests, immunoblot kits using Euro-
pean mugwort or Chinese Artemisia spp. pollen extracts, or Immuno-
CAP (w6, A. vulgaris extract); CRD has rarely been applied to
establish sensitization profiles or to direct allergen immunotherapy in
Chinese mugwort‐allergic patients. In addition, the relation between
IgE responses to different components and clinical phenotypes has
barely been explored.7 Here, we used ImmunoCAP to evaluate the
importance of IgE to four Artemisia pollen components: Art v 1 (de-
fensin‐like protein), Art ar 2 (pathogenesis‐related protein 1), Art v 3
(lipid transfer protein), and Art an 7 (putative galactose oxidase) in a
group of 240 Chinese Artemisia pollen‐allergic patients from three
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GRAPHICAL ABSTRACT
Component‐resolved diagnosis of Chinese Artemisia pollen allergic
patients helps assess the potential risk of mugwort‐associated aller-
gic asthma. Sensitization to more than two Artemisia pollen allergens
resulted in higher risk of allergic asthma, in which co‐sensitization to
Art v 1, Art v 3 and Art an 7 allergens is prominent.
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different Chinese provinces (Shanxi, Shandong, and Yunnan, respec-
tively) with characteristic seasonal Artemisia pollen counts, and
describe possible associations with demographics and clinical
phenotypes.
2 | MATERIALS AND METHODS
2.1 | Patients and symptoms
A total of 240 patients were recruited based on a convincing history
of Artemisia pollen allergy in late summer and autumn, positive results
in specific mugwort IgE tests but negative or very weak to hop pollen
(w22) by ImmunoCAPs or by quick immunoblot kit assay (EUROIM-
MUN Beijing, China or Xinhualian, Beijing, China). These 240 patients
were from three areas: 178 from Datong and Taiyuan, Shanxi Pro-
vince (SX), 30 from Yantai, Shandong Province (SD), and 32 from Quj-
ing, Yunnan Province (YN). CRD for some of the patients from SX
(110/178) has previously been reported,21 so for these, here, only the
Art ar 2 component was tested. Patients were also divided into three
age groups—children (2‐12 years old), teenagers (13‐18 years), and
adults (19‐66 years). The three areas in China showed different sea-
sonal Artemisia pollen counts: Taiyuan (Shanxi province), inland next
to the Inner Mongolia grasslands, has the highest Artemisia pollen
concentration which reaches a peak in August and September; in the
coastal city of Yantai (Shandong province), east of Shanxi, the pollen
peak is in September; and the Yunnan province, with a subtropical
and tropical monsoon climate, has a very low Artemisia pollen con-
centration, limited to October and November. Geographic areas and
Artemisia pollen count records (microscopic observation of pollen col-
lected on a slide by a simple device) were taken from a survey
report25 and are given in Figure S1.
Clinical presentations of Artemisia pollen allergy were established
by experienced clinicians through questionnaires and clinical obser-
vations and tests. Seasonal allergic asthma was defined by a history
of dyspnea, wheezing and/or coughing episodes and diagnosed by
spirometry (MasterScreen or Powercube‐Body, Germany). For some
patients (33/104) from SX and SD, asthma was confirmed by testing
for positive airway reversibility, that is, by FEV1 increasing ≥12%
after inhalation of 400 μg of salbutamol sulphate. Conjunctivitis was
defined based on symptoms such as ocular itching and tearing. The
diagnosis of atopic eczema was based on the presence of skin rash
with red, raised itchy bumps, and of allergic rhinitis on itching, sneez-
ing, runny nose, and congestion. For all clinical presentations, a clear
association of symptoms with the Artemisia pollen season was nec-
essary for a diagnosis of Artemisia pollen allergy.
Written informed consent was obtained from all participants, and
the study was approved by the local ethics committee of Second
Affiliated Hospital, College of Medicine, Zhejiang University (autho-
rization No. 2011‐R‐1 and 2013‐67‐087) in collaboration with the
Third People's Hospital of Datong, Shanxi (authorization No. 2015‐
001), Yu Huang Ding Hospital, Yantai, Shandong (authorization No.
2015‐164), and Qujing Chinese Traditional Medicine Hospital,
Yunnan, China.
2.2 | ImmunoCAP tests
All 240 subjects were tested for their specific IgE to mugwort pollen
extract (code w6) and two commercial components (nArt v 1, nArt v
3, with code w231 and w233, respectively) by ImmunoCAP (Ther-
moFisher Scientific, Uppsala, Sweden). The two additional natural
allergens Art ar 2 (GenBank MF326217) and Art an 7 (GenBank
KY428925) recently included in IUIS (http://allergen.org/) were
biotinylated and coupled to streptavidin‐conjugated ImmunoCAPs
(o212) as described previously.26 Natural Art ar 2 was purified by a
monoclonal antibody affinity chromatography (C9‐C1: obtained by
immunization from a pollen extract of Chinese mugwort A. argyi),
and its primary sequence is identical to Art v 2 as demonstrated
upon cloning (GenBank MF326222). Natural Art an 7 was purified
from A. annua extract as described previously.21 Sera with an IgE
value > 100 kUA/L were diluted and retested, with 0.35 kUA/L con-
sidered as positive cutoff.
2.3 | Statistical analyses
Data were analyzed by SPSS 21.0, with a value of P < 0.05
considered as significantly different. Frequencies of positive IgE were
analyzed by chi‐square test or Fisher's exact test and differences in
IgE levels between groups calculated by the Mann‐Whitney U test.
The Spearman correlation coefficient analysis was used to determine
correlations of IgE levels between groups, and quantitative variables
in the three areas were compared by Kruskal‐Wallis test, with Bon-
feroni correction applied in pair‐wise comparison.
3 | RESULTS
3.1 | Symptoms and sensitization profiles of
Chinese mugwort‐allergic patients
Of the 240 patients, the vast majority (95%) were diagnosed with
Artemisia pollen‐associated allergic rhinitis. In addition, 53% had con-
junctivitis, 43% allergic asthma, and 19% atopic eczema, with quite
significant geographic variation of these three symptoms (Table 1).
For IgE reactivity against the four components, Art v 1 was the most
frequently recognized allergen (81%, range 53%‐93%), ahead of Art
an 7 (80%, range 38%‐87%), Art v 3 (53%, range 9%‐66%) and Art v
Highlights
• The frequency and IgE levels of four Artemisia allergen
components in patients from SX and SD were higher
than that in YN China.
• Patients from SX and SD were more likely to have aller-
gic asthma than patients from YN China.
• Patients co-sensitization to Art v 1, Art v 3 and Art an 7
have a higher risk of developing allergic asthma.
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2 (42%, range 9%‐48%). Median IgE levels were highest against Art
v 1 (9.6 kUA/L), followed by Art an 7 (2.1 kUA/L) and Art v 3
(1.1 kUA/L), whereas the median IgE to Art ar 2 was below the cutoff
(Table 1).
The correlation of mugwort IgE levels to the sum of the
four components was very high (Spearman r = 0.92, P < .001), fit-
ting a linear regression (R2 = 0.74, Figure S2). The 11 outliers in
the bottom right corner are mainly from YN Province. For these
patients, other allergens such as Art v 4 and/or Art v 6 may play
a role.
3.2 | CRD and age
IgE levels against mugwort extract, Art ar 2, and Art an 7 were sig-
nificantly different (P < 0.05) among children, teenagers and adults
(Figure 1A), with the adult group having a significantly lower IgE to
mugwort and Art an 7 than the child and teenager group. The fre-
quency of sensitization to Art ar 2 was higher in the child group
than in the teenager and adult groups (Figure 1B). The number of
components recognized per patient was not significantly different
between age groups (Figure 1C).
3.3 | CRD and geographic background
The IgE levels against mugwort extract and four allergen components
in Shanxi (SX) and Shandong (SD) in Northern China were significantly
higher than in patients from Yunnan (YN) in Southwestern China
(P ≤ 0.001). SX patients had higher IgE levels against the two compo-
nents Art v 3 and Art an 7 than patients from SD, but not against Art v
1 and Art ar 2 (Figure 2A). The frequency of sensitization to Art v 1,
Art ar 2, and Art an 7 was similar in SX and SD, and significantly higher
than in YN. The number of SX patients sensitized to Art v 3 was signif-
icantly higher and with higher IgE level (Figure 2A,B). Most patients
from SX and SD were sensitized to 2‐4 components, while for YN
patients this was less than 2 components (Figure 2C). Multiple allergen
sensitization (3‐4 components) resulted in an elevated occurrence of
allergic asthma (P < 0.001, OR, 3.65; 95%CI, 2.11‐6.33). Patients from
SX and SD in N China were more likely to have allergic asthma (48%‐
64%) than patients from YN (3%, in SW China). Rates of conjunctivitis
were very high in YN patients, followed by SX patients, with the low-
est rate found in SD (P < 0.01) (Figure 2D).
3.4 | CRD and clinical phenotypes
For all tested patients, mugwort extract IgE values in the allergic
asthma group were higher than the non asthmatic group but not sig-
nificantly, while three components Art v 1, Art v 3, and Art an 7
showed a statistically significant difference (Figure 3A). With increas-
ing numbers of allergens recognized, the frequency of allergic asthma
increased, but this was not observed for the other three allergic symp-
toms (Figure 3B). Furthermore, the frequency of sensitization to Art v
1, Art v 3, and Art an 7 was also significantly higher in patients with
allergic asthma (Figure 3C), resulting in an approximately 3‐fold higher
risk of allergic asthma in patients sensitized to Art v 1 (OR, 3.26; 95%
CI, 1.53‐6.94; P = 0.002), Art v 3 (OR, 2.77; 95% CI, 1.63‐4.72;
P = 0.001), and Art an 7 (OR, 3.28; 95% CI, 1.58‐6.78; P = 0.001).
To exclude the influence of geographic background on association
of sensitization profiles and age with allergic asthma, analyses were
performed for the 178 patients from SX alone. There were no signifi-
cant differences between asthmatic and non asthmatic groups for IgE
values of mugwort extracts and four individual components (Fig-
ure 4A). There was a weak but significant correlation between
patients’ age and asthma symptoms (Spearman r = 0.284, P < 0.001),
with adults suffering more often from asthma than children (Table 2,
Figure 4B). Asthmatic patients had a higher frequency of IgE reactiv-
ity to three or four allergens than the non asthmatic patients (0‐2
TABLE 1 Demographics and characterization of the study population in the three provinces in China
SX SD YN Total P value
Patients, no. 178 30 32 240
Gender, female no. (%) 92 (52) 18 (60) 18 (56) 128 (53) 0.653
Age, median (range) 22 (4‐61) 23.5 (3‐66) 31.5 (6‐54) 23 (3‐66) 0.453
Symptoms (%)
Asthma 85 (48) 18 (60) 1 (3) 104 (43) <0.001
Conjunctivitis 92 (52) 7 (23) 27 (84) 126 (53) <0.001
Rhinitis 166 (93) 29 (97) 32 (100) 227 (95) 0.324
Eczema 36 (20) 2 (7) 7 (22) 45 (19) 0.201
Specific IgE, median, IQR (kUA/L)
Mugwort extract 39.3 (16.3‐78.4) 25.2 (7.5‐74.7) 2.8 (1.2‐11.9) 30.4 (10.5‐70.8) <0.001
Art v 1 11.7 (1.8‐30.3) 13.7 (4.5‐64.5) 0.4 (0.0‐5.5) 9.6 (1.1‐29.0) <0.001
Art ar 2 0.3 (0.1‐1.3) 0.3 (0.1‐0.9) 0.0 (0.0‐0.1) 0.2 (0.1‐1.0) <0.001
Art v 3 15.8 (0.1‐56.7) 0.1 (0.0‐0.7) 0.0 (0.0‐0.0) 1.1 (0.1‐44.4) <0.001
Art an 7 3.1 (1.0‐8.5) 0.9 (0.5‐3.1) 0.1 (0.0‐0.6) 2.1 (0.5‐6.3) <0.001
SD, Shandong province; SX, Shanxi province; YN, Yunnan province.
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components) (P = 0.001, OR, 2.86, 95% CI, 1.49‐5.50) (Figure 4C).
The sensitization frequency to Art v 1 (P = 0.027) and Art v 3
(P = 0.01) was significantly higher than in the non asthma group
(Table 2), and more than a 2‐fold risk of allergic asthma was found in
Artemisia pollen‐allergic patients with IgE reactivity to Art v 1 (OR,
2.64; 95% CI, 1.09‐6.36) and Art v 3 (OR, 2.30; 95% CI, 1.21‐4.37).
No significant differences were observed for the other two allergens
(Table 2). The interrelation of symptoms and sensitized allergens in
asthmatic and non asthmatic groups is shown in Figure 4D,E, with
the number of patients reacting to both Art v 1 and Art v 3 being sig-
nificantly higher (P < 0.03) in asthmatic (72.6%) than non‐asthmatic
allergy patients (48.9%).
4 | DISCUSSION
This study provides new insights in mugwort component sensitiza-
tion and clinical significance in China. From both sensitization fre-
quencies and IgE titers, we can draw a general conclusion that three
allergens qualify as major allergens in China: Art v 1, Art v 3, and Art
an 7. These results are in line with those from Europe27 and our
immunoblots of three widely recognized allergens in Northern
China.21 Art v 1 and Art an 7 were consistently the most prevalent
(more than 80%) in the three areas, indicating that these two aller-
gens are biomarkers of Artemisia pollens inducing allergic reactions.
From the observations obtained from Shanxi and Shandong, we esti-
mate the prevalence of Art v 1 at 84%‐93% in Northern China,
which is quite similar to that of the mugwort‐allergic patients in Eur-
ope but higher than in North America.24,27 Median Art v 1 IgE value
was also similar to those in Northern Europe. Art an 7 was assumed
to be in the same allergen group as Art v 60 kDa, which was
reported about 20 years ago and has recently been identified as a
putative galactose oxidase with a very high rate of sensitization
(around 90%).21 In the present study, the frequency of Art an 7 sen-
sitization was quite similar, at 87% in SX and slightly lower in SD.
The prevalence and degree of sensitization to Art v 3 were quite dif-
ferent in these two areas, with 66% in SX and 25% in SD. Very sig-
nificant differences with respect to recognition of Art v 3 amongst
mugwort‐allergic patients have also been reported in Europe.20
Although the prevalence of 66% in SX is quite similar to that
reported in central Europe,10,28 IgE levels are much higher. The strik-
ing difference between SX and SD is most likely explained by a
Mugwort Art v 1 Art ar 2 Art v 3 Art an 7
0.01
0.1
1
10
100
1000
sI
gE
 (k
U
A
/L
)
Children (2-12 year)
Teenager (13-18 year)
Adult (19-66 year)
0.35
*****
*
Art v 1 Art ar 2 Art v 3 Art an 7
0
20
40
60
80
100
Fr
eq
ue
nc
y(
%
)
Fr
eq
ue
nc
y(
%
)
Children (2-12 year) Teenager (13-18 year) Adult (19-66 year) Children (2-12 year) Teenager (13-18 year) Adult (19-66 year)
*
0 1 2 3 4
0
10
20
30
40
Allergens no.
(A)
(B) (C)
F IGURE 1 Mugwort extract and four components tested in different age groups. IgE levels (A), frequency (B) and number of sensitized
allergens, 0 indicates none of the four tested components were positive, and 1, 2, 3, and 4 represent the number of positive individual
allergens Art v 1, Art ar 2, Art v 3, and Art an 7 (C). Significant differences are shown: *P < 0.05, **P < 0.01, ***P < 0.001
GAO ET AL. | 5
higher pollen load in SX and possibly by different Artemisia species
dominating in the regions.7,28 Art ar 2 had the least prevalence
(42%‐48%) and IgE levels, being close to the 58% for Art v 2
reported in Europe.29
This is the first study to explore a possible relationship between
Artemisia pollen molecular sensitization profiles and seasonal allergic
asthma. Mugwort‐allergic patients sensitized to three or four aller-
gens had a higher risk of asthma (56.4%, OR is 2.86‐3.65) than
patients sensitized to two or less (31.1%). In line with this, in YN,
with very low Artemisia pollen exposure (ratio of the total pollen
count in peak month in SX, SD, and YN is 10:6:1, Figure S1) and the
majority of patients being sensitized to ≤2 allergens, only one in 30
patients had allergic asthma (Figure 2D). Sensitization to a higher
number of allergens is usually accompanied by a higher IgE level and
potential broader cross‐reactivity to allergens of pollens from not
only Artemisa, but also from other genera in the Asteraceae family,
such as Dendranthema, Helianthus, Xanthium, and Ambrosia. Art v 1
was ranked highest in inducing asthma because of its higher preva-
lence and OR values related to asthma. Art v 3 is the second major
allergen, although its prevalence was lower than Art v 1; sensitized
patients can have very high IgE levels in Northern China, and allergic
reactions due to cross‐reactivity to various fruits, peanut, soybean,
wheat, sunflower seed have been reported in this study and
previously.16,30,31
The four components used are natural proteins, so potential
CCD involvement in the IgE binding cannot be excluded for those
allergens known to be glycoproteins, that is, Art v 1, Art ar 2, and
Art an 7. Art v 3 is a lipid transfer protein and is not glycosylated.
Of the three glycoproteins, the Art ar 2 and Art an 7 carry typical
CCD‐like N‐linked glycans,21,29 whereas Art v 1 has O‐linked glycans
that have also been described to be recognized by IgE of some
patients.32 It can therefore not be excluded that both types of gly-
can‐specific IgE antibodies play a role in recognition of the three
allergens. However, we think the role of CCD‐specific IgE is quite
limited in Chinese patients, as in our recent paper on Art an 7,21 we
tested CCD in 21 patients, and found a low frequency of positivity
(4/21) with low IgE levels. Moreover, our ongoing research indicates
that recombinant of Art v 1 has similar IgE binding potency in mug-
wort‐allergic patients, suggesting a minor role for IgE binding to Art
v 1's O‐linked glycans.
A small number of sera demonstrated significantly higher IgE bind-
ing to mugwort extract than to the sum of IgE responses against the
four components tested in the present study (Figure S2). This suggests
that for these patients other components are probably relevant. Simi-
lar to what was reported earlier,22 Art v 5 seems to be of minor impor-
tance, and ten of these sera were negative for IgE reactivity to rArt an
5. We speculate Art v 4 and Art v 6 are most likely to be the missing
components because of their broad cross‐reactivity.33
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Because of the geographic difference associated with different
Artemisia species distribution and pollen load in China, the pattern
of Artemisia pollen allergen sensitization between the north and
south China is dramatically different. Here, we selected two com-
mercially available components from European (A. vulgaris) and two
noncommercially available from Chinese mugwort (A. argyi and
A. annua). This choice was made to combine convenience (commer-
cial availability) with local relevance (dominant Chinese mugwort
species). It is however unlikely that the different species display
much difference in IgE binding potencies because IgE responses are
expected to be highly cross‐reactive between species within a
genus. This assumption is based on ongoing investigations into
sequence identity and variation of seven homologous allergen
groups in seven Artemisia species. The results so far indicate that
sequence identity is very high, perhaps with the exception of group
3, that is, the LTPs that show some more heterogeneity. Therefore,
it is safe to assume that the total Artemisia pollen load (exposure)
has the largest impact on the degree of mugwort pollen allergy
prevalence and its clinical phenotypes, not the possible geographic
variation in mugwort species. Also a recent study provides support
for this in showing that regional differences in pollen induced aller-
gic rhinitis are associated with pollen load due to environmental
and climate conditions in Inner Mongolia, China.34 Inner Mongolia
is north of Shanxi Province, where we enrolled 66% of patients in
this research.
Most mugwort allergy patients have previously been found to
first suffer mild allergic rhinitis symptoms at median age of
27.9 years, with a transition to asthma usually taking about 5 years
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(median age of 32.6 years),7 and becoming more common after mid-
dle age. In this study, the median age was found to be 23 years for
allergic rhinitis, and 28 years for allergic asthma, 5 years earlier than
previous reports. This difference in the process toward allergic
asthma in teenagers may be related to higher IgE values of extract
and components (Figure 1A). The main reason is perhaps the signifi-
cantly higher exposure to Artemisia pollen due to the warmer climate
(annual average temperature +1.5°C) and uncontrolled growth and
spread of several dominant Artemisia plants in waste and marginal
lands or roadsides in the suburbs and countryside in North China
over the last 30 years. A comparison over 30 years in Taiyuan,
Shanxi Province, showed the total Artemisia spp. pollen count had
increased 36%, with the peak lasting 2 weeks longer.35 This indicates
a need to control the growth and spread of Artemisia plants in the
wild.
In conclusion, different sensitization patterns and symptoms
were observed in mugwort‐allergic patients from Northern and
Southern China. Sensitization to three or more mugwort allergens
resulted in a higher risk of allergic asthma.
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F IGURE 4 IgE reactivity of asthmatic
and non‐asthmatic patients from Shanxi
province. A, specific IgE levels to mugwort
extract and four component allergens (Art
v 1, Art ar 2, Art v 3 and Art an 7); B,
distribution of asthmatic and non
asthmatic patients among different age
groups; C, multiple allergens sensitizations
in asthma and non asthma groups, 0‐none
of the four tested components were
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number of positive individual Art v 1, Art
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diagrams of the interrelation of sensitized
allergens in asthma and non asthma
groups; the median is shown as a red solid
line, significant differences: *P < 0.05,
**P < 0.01, ***P < 0.001
TABLE 2 Characterization of asthmatic and non asthmatic
patients from Shanxi
Patients, no. (%)
Non
asthmatic Asthmatic Total P value
Patients, no. (%) 93 (52) 85 (48) 178 (100)
Age median (range) 16 (6‐59) 28 (4‐61) 22 (4‐61) <0.001
Allergen positive no. (%)
Art v 1 73 (79) 77 (91) 150 (84) 0.027
Art ar 2 44 (47) 42 (49) 86 (48) 0.779
Art v 3 53 (57) 64 (75) 117 (66) 0.01
Art an 7 77 (83) 78 (92) 155 (87) 0.075
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